查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2005129

急性缺血性脑中风诊断市场：按产品类型、检测类型、疾病类型、技术和最终用户划分－2026-2032年全球市场预测

Acute Ischemic Stroke Diagnosis Market by Product Type, Test Type, Disease Type, Technology, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，急性缺血性脑中风诊断市场价值将达到 39.9 亿美元，到 2026 年将成长至 42.4 亿美元，到 2032 年将达到 64.7 亿美元，复合年增长率为 7.13%。

主要市场统计数据
基准年 2025 39.9亿美元
预计年份：2026年 42.4亿美元
预测年份 2032 64.7亿美元
复合年增长率 (%) 7.13%

为了支持策略决策，确定紧急临床优先事项和技术促进因素，以重组急性缺血性脑中风。

急性缺血性脑中风仍然是全球范围内导致发病率和死亡率的主要原因之一，因此需要快速、实证的诊断策略来优化临床疗效。在时间紧迫的临床过程中，随着新的生物标记、先进的影像技术和床边解决方案的整合，我们的诊断方式也在不断发展，这些技术能够缩短诊断时间并实现更精准的干预。随着临床团队不断完善分流通讯协定，转运前意识、院内诊断和介入准备之间的相互作用对于降低残疾率和改善康復过程至关重要。

探索加速诊断和重塑急性缺血性脑中风治疗的关键技术进步和护理路径创新。

急性缺血性脑中风的诊断正经历着一场变革，这主要得益于技术进步、工作流程的重新设计以及以速度和准确性为优先的新型诊疗模式。诸如快速CT灌注影像通讯协定和复杂的MRI序列等先进影像技术正日益融入超急性期诊疗流程，有助于区分缺血半暗带组织和不可逆损伤区域，从而辅助制定再灌注治疗方案。同时，携带式影像设备和远端医疗平台使得在社区和基层医疗机构开展诊断成为可能，远距专家能够指导时间紧迫的干预措施。

本研究评估了关税制度的变化和跨境贸易的复杂性如何影响急性中风诊断的筹资策略和供应链韧性。

关税政策和跨境贸易趋势的变化会对用于诊断急性缺血性脑中风的诊断设备和耗材的供应和成本结构产生重大影响。 2025年，不断上涨的关税压力影响了医疗影像设备组件、检测试剂和专用一次性用品的供应链，迫使采购团队重新评估其供应商关係和筹资策略。因此，各机构纷纷拓展供应管道，并加强关键物资的库存弹性，以避免重症病患的救治工作中断。

综合产品、测试、疾病、技术和最终用户观点，我们确定了差异化的采用路径和临床效用。

从多个细分观点了解市场，有助于明确不同的临床和营运需求如何驱动需求和应用模式。按产品类型划分，诊断路径包括血液生物标记检测、颈动脉超音波、CT扫描仪和MRI系统等影像学检查以及脑电图，每种方法都发挥互补作用，从快速分诊到病因分类。按检测类型划分，临床工作流程依赖临床实验室和代谢指标检测，其中临床实验室还包括基于血液检测和影像学的评估，以指导急性治疗方案的选择。依疾病类型划分，栓塞性中风、腔隙性梗塞和血栓性中风的诊断重点各不相同，每种疾病在影像学选择、生物标记解读和二级预防策略方面都有其独特的意义。按技术划分，检测工具涵盖从基于生物标记的检测到就地检验平台，这些工具在结果出具时间、所需基础设施和操作人员培训方面存在差异。根据最终用户，有关实施和采购的决策由门诊手术中心、诊断中心、医院和诊所以及研究实验室主导，每个机构的病例量、监管限制和临床期望都各不相同。

检查基础设施、临床通讯协定和实施趋势的区域差异，以协调不同医疗保健环境中的诊断策略。

区域趋势对急性缺血性脑中风的诊断技术应用、基础设施投资和临床通讯协定製定有显着影响。在美洲，先进的三级医疗中心和综合医疗网络往往主导着高端影像设备、移动卒中单元和生物标誌物研究的应用，而同一区域内的遍远地区仍然面临着医疗资源匮乏的挑战，需要远距远端医疗和中心辐射式医疗模式。欧洲、中东和非洲的医疗体系差异显着。核心都市区医疗机构在以卒中网路为重点的公共卫生倡议的支持下，能够提供优质的医疗服务，而其他地区的资源限制则促使人们寻求实用且扩充性的诊断解决方案。在亚太地区，医疗基础设施的快速现代化和影像技术的巨额投资扩大了临床诊疗能力，但保险报销体系和医护人员配备方面的差异导致了先进诊断技术应用方面的差异。

对整合成像、快速检测和软体驱动的工作流程融合的竞争格局进行分析，重新定义了诊断差异化。

急性缺血性脑中风诊断领域的主要企业提供差异化的产品系列，涵盖影像硬体、临床检测、照护现场(POC) 平台和整合软体解决方案。市场领导者透过软体功能完善现有影像平台，从而提高工作流程效率和定量解读能力；而创新型新参与企业则专注于生物标记发现、快速检测以及用于急诊室和院前急救的紧凑型诊断设备。影像设备供应商、检测开发人员和临床机构之间的合作日益普遍，从而能够共同开发整合诊断流程，加速临床检验和应用。

为开发人员和医疗保健领导者提供可操作的策略重点，以加速产品应用并确保可持续的临床和商业性优势。

产业领导者应采取一系列切实可行的优先事项，在控制营运风险的同时，加速产品在临床上的应用。首先，透过投资互通性、以使用者为中心的设计以及减少应用障碍的培训项目，使产品开发与实际临床工作流程保持一致。其次，优先进行临床检验研究，以证明产品能够显着缩短诊断时间并改善治疗方案选择，从而增强对保险公司和医院的价值提案。第三，透过实现生产和分销管道多元化以及谈判签订稳定的合同，确保关键组件和试剂的供应，从而解决供应链脆弱性问题。

为了得出确切的结论，我们采用了严谨的多面向调查方法，结合了临床证据、专家意见和供应链分析。

本调查方法整合了多种途径，包括临床文献回顾、专家访谈、技术评估和供应链分析，旨在整体情况诊断环境。证据整合利用同侪审查的临床研究、指引说明和已发表的技术评估，来评估临床效用和对工作流程的影响。透过对神经科医生、急诊科医生、放射科医生、实验室主管和采购经理的访谈，确定了实际限制因素和推广应用驱动因素；同时，从供应商描述和产品资料表中获取了有关设备功能和服务模式的技术背景资讯。

本文总结了决定急性中风诊断有效性和患者预后的临床、技术和操作因素的汇聚。

总之，急性缺血性脑中风的诊断正处于转折点，随着技术创新、临床流程的重新设计以及供应链因素的交汇，临床实践正在重塑。快速影像、新型生物标记的应用以及就地检验总体上能够实现更准确、更及时的决策，但区域和政策因素会影响这些技术实施的可行性和速度。积极参与工作流程整合、临床检验和采购弹性建构的相关人员，将更有能力将诊断技术的进步转化为病患预后的可衡量改善。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：急性缺血性脑中风诊断市场：依产品类型划分

  • 血液生物标记
  • 颈动脉超音波检查
  • 诊断影像
    • 电脑断层扫描（CT）扫描仪
    • 磁振造影系统
  • 脑电图（EEG）

第九章：依侦测类型分類的急性缺血性脑中风诊断市场

  • 临床试验
    • 验血
    • 影像检查
  • 代谢指标

第十章：急性缺血性脑中风诊断市场：依疾病类型划分

  • 栓塞
  • 湖相特性
  • 血栓性

第十一章：急性缺血性脑中风诊断市场：依技术划分

  • 基于生物标记的检测
  • 即时检测

第十二章：急性缺血性脑中风诊断市场：依最终用户划分

  • 门诊手术中心
  • 诊断中心
  • 医院和诊所
  • 研究机构

第十三章：急性缺血性脑中风诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：急性缺血性脑中风诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：急性缺血性脑中风诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国急性缺血性脑中风诊断市场

第十七章：中国急性缺血性脑中风诊断市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Aidoc Medical Ltd.
  • BIOTRONIK SE & Co KG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Canon Medical Systems Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE Healthcare Technologies Inc.
  • Hitachi, Ltd.
  • Integral Diagnostics（IDX）Group
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips NV
  • Mediso Ltd.
  • Medtronic PLC
  • Merck & Co.
  • Neusoft Corporation
  • Nihon Kohden Corporation
  • Planmed Oy
  • Samsung Electronics Co. Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shimadzu Corporation
  • Shionogi & Co., Ltd.
  • Siemens Healthineers
  • Stryker Corporation
  • Toshiba International Corporation
Product Code: MRR-B16853776EA8

The Acute Ischemic Stroke Diagnosis Market was valued at USD 3.99 billion in 2025 and is projected to grow to USD 4.24 billion in 2026, with a CAGR of 7.13%, reaching USD 6.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.99 billion
Estimated Year [2026] USD 4.24 billion
Forecast Year [2032] USD 6.47 billion
CAGR (%) 7.13%

Framing the urgent clinical priorities and technological drivers reshaping acute ischemic stroke diagnosis to inform strategic decision-making

Acute ischemic stroke remains a leading cause of morbidity and mortality worldwide and demands rapid, evidence-based diagnostic strategies to optimize clinical outcomes. The diagnostic landscape is evolving as time-critical pathways integrate novel biomarkers, advanced imaging modalities, and point-of-care solutions that shorten time-to-diagnosis and enable more targeted interventions. As clinical teams refine triage protocols, the interplay between pre-hospital recognition, in-hospital diagnostics, and interventional readiness has become central to reducing disability and improving recovery trajectories.

In the context of rising expectations for personalized care, diagnostic stakeholders must balance speed, accuracy, and resource intensity. Technological advances in imaging and laboratory diagnostics have expanded the tools available to clinicians, but they also introduce complexity in procurement, training, and workflow integration. Consequently, institutional leaders and clinical directors face decisions about investment priorities that directly influence patient throughput, treatment windows, and cross-disciplinary collaboration. The subsequent sections synthesize the key shifts in technology, policy, and practice that are shaping acute ischemic stroke diagnosis and highlight strategic considerations for health systems, device manufacturers, and diagnostic laboratories.

Exploring the pivotal technological advancements and care pathway innovations that are accelerating diagnosis and reshaping acute ischemic stroke management

The landscape of acute ischemic stroke diagnosis is undergoing transformative shifts driven by technological refinement, operational redesign, and emerging care models that prioritize speed and precision. Advanced imaging techniques, such as rapid CT perfusion protocols and enhanced MRI sequences, are increasingly integrated into hyperacute workflows to differentiate penumbral tissue from irreversibly damaged areas, thereby informing reperfusion decisions. At the same time, portable imaging and telemedicine platforms have extended diagnostic reach into community and rural settings, enabling remote expertise to guide time-sensitive interventions.

Concurrently, molecular diagnostics and blood-based biomarkers are moving from research settings toward clinical applicability, offering the potential to stratify etiologies and identify patients unlikely to benefit from certain reperfusion strategies. Point-of-care testing technologies are reducing turnaround times for critical parameters and supporting earlier clinical decision-making in emergency and pre-hospital environments. These technological advances are coupled with care pathway innovations such as direct-to-CT triage, mobile stroke units, and streamlined transfer protocols, all of which seek to compress door-to-needle and door-to-groin puncture intervals. Together, these shifts enhance the precision of diagnosis and expand the possibilities for patient-centered, evidence-based acute stroke care.

Assessing how shifting tariff regimes and cross-border trade complexities have influenced procurement strategies and supply chain resilience in acute stroke diagnostics

Tariff policy changes and cross-border trade dynamics can materially influence the availability and cost structure of diagnostic equipment and consumables that support acute ischemic stroke diagnosis. In 2025, heightened tariff pressures affected the supply chains for medical imaging components, laboratory reagents, and specialized disposables, prompting procurement teams to reassess vendor relationships and sourcing strategies. As a result, organizations sought to diversify supply channels and to increase inventory resilience for critical items to avoid disruptions in hyperacute care delivery.

These shifts prompted healthcare providers and diagnostics suppliers to re-evaluate total landed costs and to explore alternative sourcing arrangements, including regional manufacturing partnerships and consolidated procurement frameworks. Clinicians and administrators had to balance the potential for short-term cost increases against the clinical imperative of maintaining rapid diagnostic throughput, which is directly tied to patient outcomes. In response, some systems prioritized capital investments that reduced dependency on imported consumables, while others negotiated long-term supply contracts to stabilize prices and ensure continuity of care. Overall, tariff-related headwinds encouraged a more strategic approach to supply chain management and accelerated considerations for localized production and redundancy planning.

Integrating product, test, disease, technology, and end-user perspectives to reveal differentiated adoption pathways and clinical utility drivers

Understanding the market through multiple segmentation lenses clarifies how distinct clinical and operational needs drive demand and adoption patterns. Based on product type, diagnostic pathways incorporate blood biomarker assays, carotid ultrasound, diagnostic imaging modalities including computed tomography scanners and MRI systems, and electroencephalography, each serving complementary roles from rapid triage to etiologic classification. Based on test type, the clinical workflow relies on lab tests and metabolic panels, with lab tests further encompassing blood tests and imaging-based assessments that inform acute therapeutic choices. Based on disease type, diagnostic priorities differ for embolic, lacunar, and thrombotic strokes, as each presentation carries unique implications for imaging selection, biomarker interpretation, and secondary prevention strategies. Based on technology, detection tools span biomarker-based assays and point-of-care testing platforms, which vary in turnaround time, required infrastructure, and operator training. Based on end-user, adoption and procurement decisions are driven by ambulatory surgical centers, diagnostic centers, hospitals and clinics, and research laboratories, each with distinct volume profiles, regulatory constraints, and clinical expectations.

By synthesizing these segmentation perspectives, stakeholders can align product development, clinical validation, and commercialization strategies with the specific needs of different user types and disease presentations. For example, solutions optimized for point-of-care use will prioritize rapid turnaround and simplified workflows, whereas imaging investments will focus on throughput, compatibility with stroke protocols, and integration with interventional teams. This multi-dimensional view supports targeted innovation and more effective deployment across diverse clinical settings.

Examining regional variations in infrastructure, clinical protocols, and adoption dynamics to align diagnostic strategies across diverse healthcare environments

Regional dynamics exert a profound influence on diagnostic adoption, infrastructure investment, and clinical protocols for acute ischemic stroke. In the Americas, advanced tertiary centers and integrated health networks often lead in deploying high-end imaging, mobile stroke units, and biomarker research, while rural regions within the same geography continue to face access challenges requiring telemedicine and hub-and-spoke models. In Europe, the Middle East & Africa, healthcare systems vary widely, with pockets of excellence in urban centers supported by public health initiatives that emphasize stroke networks, contrasted with areas where resource constraints necessitate pragmatic, scalable diagnostic solutions. In Asia-Pacific, rapid modernization of healthcare infrastructure and significant investments in imaging have expanded capacity, yet heterogeneity in reimbursement and workforce availability shapes differential uptake of advanced diagnostics.

These regional contrasts influence where vendors prioritize regulatory approvals, localization of service models, and partnerships with health ministries and hospital groups. Moreover, prevalence patterns, emergency medical services maturity, and regional training programs affect the feasibility of implementing advanced diagnostic workflows. Consequently, companies and health systems must craft regionally tailored strategies that consider infrastructure maturity, clinical practice norms, and the pragmatic needs of providers and patients across diverse settings.

Profiling the competitive landscape where integrated imaging, rapid assays, and software-enabled workflows converge to redefine diagnostic differentiation

Key companies competing in acute ischemic stroke diagnostics are advancing differentiated portfolios that span imaging hardware, laboratory assays, point-of-care platforms, and integrated software solutions. Market leaders complement established imaging platforms with software enhancements that improve workflow efficiency and quantitative interpretation, while innovative entrants concentrate on biomarker discovery, rapid assay formats, and compact diagnostic devices intended for emergency and pre-hospital use. Partnerships between imaging vendors, assay developers, and clinical institutions are increasingly common, enabling co-development of integrated diagnostic pathways that accelerate clinical validation and adoption.

Competitive dynamics also reflect a balance between scale and specialization. Large manufacturers leverage global service networks and established installation bases to sell bundled solutions that integrate scanners, informatics, and training. Meanwhile, agile startups often focus on niche performance advantages such as ultra-rapid assays or AI-enhanced image analysis, aiming to prove clinical impact through targeted trials and strategic collaborations. Overall, the competitive landscape rewards interoperability, regulatory foresight, and demonstrable improvements in diagnostic timelines and decision accuracy, creating opportunities for both consolidation and strategic alliances.

Actionable strategic priorities for developers and healthcare leaders to accelerate adoption and secure durable clinical and commercial advantages

Industry leaders should pursue a set of actionable priorities that accelerate clinical impact while managing operational risk. First, align product development with real-world clinical workflows by investing in interoperability, user-centered design, and training programs that reduce adoption friction. Second, prioritize clinical validation studies that demonstrate meaningful reductions in diagnostic time and improvements in treatment selection, thereby strengthening value propositions for payers and hospitals. Third, address supply chain vulnerabilities by diversifying manufacturing and distribution channels and by negotiating stable agreements that preserve access to critical components and reagents.

Furthermore, organizations should engage payer and regulatory stakeholders early to clarify reimbursement pathways and to design studies that meet evidentiary expectations. Strategic collaborations with emergency medical services, regional stroke networks, and academic centers can accelerate adoption and generate robust clinical data. Finally, invest in scalable service models and managed offerings that reduce total cost of ownership for health systems, and consider targeted commercialization strategies that match product tiering to the capacities of different end-users. Taken together, these actions will enhance market relevance while supporting clinicians in delivering faster, more accurate stroke diagnosis.

Describing a rigorous multi-source research approach combining clinical evidence, expert insights, and supply chain analysis to support robust conclusions

The research methodology integrates a multi-source approach combining clinical literature review, expert interviews, technology assessments, and supply chain analysis to produce a holistic view of the diagnostic landscape. Evidence synthesis draws on peer-reviewed clinical studies, guideline statements, and published technology evaluations to assess clinical utility and workflow implications. Interviews with neurologists, emergency physicians, radiologists, laboratory directors, and procurement leaders informed practical constraints and adoption drivers, while vendor briefings and product datasheets provided technical context on device capabilities and service models.

Supply chain and policy analyses relied on customs and trade documentation, procurement tender information, and public sector policy announcements to evaluate factors affecting equipment and reagent availability. Where appropriate, case examples from high-performance stroke centers illustrated best practices in pathway redesign and technology integration. Throughout the methodology, triangulation of multiple information streams ensured that conclusions reflect clinical realities, operational constraints, and technological trajectories relevant to acute ischemic stroke diagnosis.

Summarizing the converging clinical, technological, and operational forces that will determine diagnostic effectiveness and patient outcomes in acute stroke

In conclusion, acute ischemic stroke diagnosis is at an inflection point where technological innovation, pathway redesign, and supply chain considerations converge to reshape clinical practice. Rapid imaging, emergent biomarker applications, and point-of-care testing collectively enable more precise and timely decision-making, while regional and policy factors influence the feasibility and pace of adoption. Stakeholders who proactively address workflow integration, clinical validation, and procurement resilience will be best positioned to translate diagnostic advances into measurable improvements in patient outcomes.

Looking forward, the sustained focus on reducing time-to-treatment, combined with iterative improvements in diagnostic accuracy, will continue to drive investment and collaboration across clinical, commercial, and policy domains. By emphasizing interoperability, evidentiary rigor, and adaptive supply strategies, healthcare providers and industry partners can ensure that the next generation of diagnostic tools delivers both clinical value and operational sustainability for acute ischemic stroke care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Ischemic Stroke Diagnosis Market, by Product Type

  • 8.1. Blood Biomarker
  • 8.2. Carotid Ultrasound
  • 8.3. Diagnostic Imaging
    • 8.3.1. Computed Tomography (CT) Scanner
    • 8.3.2. MRI System
  • 8.4. Electroencephalography

9. Acute Ischemic Stroke Diagnosis Market, by Test Type

  • 9.1. Lab Tests
    • 9.1.1. Blood Test
    • 9.1.2. Imaging Tests
  • 9.2. Metabolic Panel

10. Acute Ischemic Stroke Diagnosis Market, by Disease Type

  • 10.1. Embolic
  • 10.2. Lacunar
  • 10.3. Thrombotic

11. Acute Ischemic Stroke Diagnosis Market, by Technology

  • 11.1. Biomarker-Based Detection
  • 11.2. Point Of Care Testing

12. Acute Ischemic Stroke Diagnosis Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Centers
  • 12.3. Hospitals & Clinics
  • 12.4. Research Laboratories

13. Acute Ischemic Stroke Diagnosis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Acute Ischemic Stroke Diagnosis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Acute Ischemic Stroke Diagnosis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Acute Ischemic Stroke Diagnosis Market

17. China Acute Ischemic Stroke Diagnosis Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Aidoc Medical Ltd.
  • 18.7. BIOTRONIK SE & Co KG
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Boston Scientific Corporation
  • 18.10. Canon Medical Systems Corporation
  • 18.11. F. Hoffmann-La Roche Ltd.
  • 18.12. Fujifilm Holdings Corporation
  • 18.13. GE Healthcare Technologies Inc.
  • 18.14. Hitachi, Ltd.
  • 18.15. Integral Diagnostics (IDX) Group
  • 18.16. Johnson & Johnson Services, Inc.
  • 18.17. Koninklijke Philips N.V.
  • 18.18. Mediso Ltd.
  • 18.19. Medtronic PLC
  • 18.20. Merck & Co.
  • 18.21. Neusoft Corporation
  • 18.22. Nihon Kohden Corporation
  • 18.23. Planmed Oy
  • 18.24. Samsung Electronics Co. Ltd.
  • 18.25. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 18.26. Shimadzu Corporation
  • 18.27. Shionogi & Co., Ltd.
  • 18.28. Siemens Healthineers
  • 18.29. Stryker Corporation
  • 18.30. Toshiba International Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)